Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $525.1 million.

  • Ligand Pharmaceuticals' Short-term Investments rose 23658.03% to $525.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $525.1 million, marking a year-over-year increase of 23658.03%. This contributed to the annual value of $183.9 million for FY2024, which is 2477.21% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Short-term Investments stood at $525.1 million, which was up 23658.03% from $177.4 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Short-term Investments high stood at $525.1 million for Q3 2025, and its period low was $117.3 million during Q3 2022.
  • Its 5-year average for Short-term Investments is $221.1 million, with a median of $189.0 million in 2022.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Short-term Investments tumbled by 6087.44% in 2022 and then soared by 23658.03% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Short-term Investments (Quarter) stood at $321.6 million in 2021, then tumbled by 48.11% to $166.9 million in 2022, then dropped by 11.69% to $147.4 million in 2023, then rose by 24.77% to $183.9 million in 2024, then soared by 185.63% to $525.1 million in 2025.
  • Its last three reported values are $525.1 million in Q3 2025, $177.4 million for Q2 2025, and $160.9 million during Q1 2025.